Aim: Second-generation antipsychotics are commonly used to treat schizophrenia, but may cause metabolic syndrome (MetS) in a subset of patients. The mechanisms of antipsychoticrelated metabolic changes remain to be established, especially in first-episode psychosis (FEP) patients.
| INTRODUCTION
Metabolic syndrome (MetS) and other cardiovascular risk factors are highly prevalent in people with schizophrenia (SCZ). MetS (comprising obesity, hyperlipidemia, hyperglycemia and hypertension) is present in one-third of these patients (McEvoy et al., 2005; Mitchell, Vancampfort, De Herdt, Yu, & De Hert, 2013) . The report of Parks, Svendsen, Singer, and Foti (2006) has demonstrated that people with SCZ die on average 25 years earlier than those in general population, and although suicide and other un-natural causes account for about 40% of excess mortality, roughly 60% of premature deaths are from natural causes, such as cardiovascular and pulmonary diseases.
Analysis of literature shows an association between MetS and SCZ , suggesting that metabolic phenotype is intrinsic to SCZ. Before the antipsychotic drug era, cohort studies revealed increased incidence of abnormal glucose metabolism in people with SCZ (Henneman, Altschule, & Goncz, 1954) . These observations are in line with cross-sectional results demonstrating that the prevalence of diabetes is greater in patients of SCZ compared to the general population (Kohen, 2004) . A recent meta-analysis has confirmed these findings, and has revealed impaired glucose tolerance (IGT) in antipsychotic-naïve first-episode psychosis (FEP) patients, as compared to control subjects (CS) (Greenhalgh et al., 2017) . IGT has also been demonstrated in non-psychotic, first-degree relatives of patients of SCZ, further indicating a heritable phenotype that tracks with the risk of psychosis, but is independent of the actual development of a psychotic disorder (Spelman, Walsh, Sharifi, Collins, & Thakore, 2007) . The risk of metabolic abnormalities further increases significantly with the duration of disease with those who have chronic disease showing increased rates of metabolic dysfunction compared to FEP patients and antipsychotic-naïve FEP patients . In part, these cardiometabolic risk factors are attributable to unhealthy lifestyle, including poor diet and sedentary behaviour (De Hert, Schreurs, Vancampfort, & VAN Winkel, 2009 ).
In addition, the treatment of choice in SCZ is antipsychotic medications, and over recent years it has become apparent that antipsychotic agents can have a negative impact on some of the modifiable risk factors (De Hert et al., 2009) . Concerns regarding the metabolic side-effects of antipsychotic drugs greatly increased following the introduction of the "second generation" or "atypical" drugs, which have come to dominate the antipsychotic drug market.
Interestingly, antipsychotic drugs have long been known to cause immunomodulatory effects, targeting cytokine networks and raising the possibility of an alternative explanation for the actions of these agents (Kato et al., 2011) . Studies on the effect of antipsychotic treatment on inflammation, and more specifically on cytokine levels, have demonstrated inconsistent findings, showing an increase, a decrease or unchanged levels of cytokines after antipsychotic treatment (Zajkowska & Mondelli, 2014) . One possible explanation for the varying findings is that antipsychotic agents might exert different effects on the immune system, having both a direct anti-inflammatory activity and an indirect pro-inflammatory activity, mediated by their effect on weight gain and increased adiposity (Mondelli & Howes, 2014) .
The observation that metabolic disorder has been associated with low-grade systemic inflammatory conditions has led to studies linking these two pathways. The immune response and metabolic regulation are highly integrated, and their proper functioning is interdependent. Indeed, obesity, insulin resistance and type II diabetes have been shown to be closely associated with chronic inflammation, characterized by the activation of inflammatory signalling pathways and by abnormal cytokine production (Hotamisligil, 2006) . It is possible that such mechanisms are also operating in psychosis. Moreover, it could be that existence of the low-grade inflammation and antipsychotic treatment contributes to the metabolic abnormalities seen in SCZ. Therefore, studies in antipsychotic-naïve FEP patients with normal weight are preferable to better understand the role of inflammation in SCZ and the antipsychotic drug treatment impact on the metabolic parameters. Despite the above reported evidence, little is known regarding the relationship between inflammation and meta- we have demonstrated that antipsychotic-naïve FEP patients had significantly elevated levels of epidermal growth factor (EGF), interleukin-4 (IL-4) and IL-6 and reduced level of IL-1β compared to CS. Furthermore, 7 months of antipsychotic drug treatment reduced significantly levels of EGF, vascular endothelial growth factor (VEGF), interferon-γ (INF-γ), IL-2, IL-4, IL-6, IL-8 and IL-1α in these patients compared to the premedication levels of these markers, and elevated body mass index (BMI) (Haring et al., 2015) . To elaborate our previous results and to establish the concurrent impact of antipsychotic treatment on inflammatory and metabolic biomarkers as well as BMI, we implemented alternative biochip array technology, which allowed to perform simultaneous assessment of metabolic and inflammatory biomarkers on the same cohort.
The goal of the present study was to examine pre-treatment inflammatory and metabolic status of FEP patients compared to CS and analyse the development of signs of MetS in FEP patients in response to 7-month antipsychotic treatment. In the first set of our study, differences in BMI, and also in inflammatory [ferritin, IL-6, IL-1α, tumour necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1)], and metabolic (C-peptide, insulin, leptin, adiponectin and resistin) biomarkers were compared between FEP patients and CS. Second, these indices were compared before and after 7-month antipsychotic treatment in FEP patients group and also between treated patients and CS groups to demonstrate the 7-month antipsychotic treatment effect on BMI and the measured biomarkers levels. only with antipsychotics, but 5 patients additionally needed mood stabilizers and 6 patients also received antidepressants or hypnotics.
Thirty-seven mentally healthy subjects participated in the study as CS (16 males and 21 females, mean age 24.8 AE 0.86 years). The CS sample was recruited by advertising in the same geographical area the FEP patients came from. Both patients and CS were interviewed by experienced psychiatric doctors in order to avoid the inclusion of subjects as controls with mental disorders. Exclusion criteria for the control group also included psychotic disorders among close relatives.
The study was approved by the Ethics Committee of the University of Tartu, Estonia. Written informed consent was also obtained from all participants.
The sample of this study contains same participants as our previous study by Haring et al. (2015) 2.2 | Procedure (Kay, Flszbein, & Opfer, 1987) , a rating instrument that evaluates the presence and severity of positive, negative and general psychopathology using 30 items, each scored from 1 (absent) to 7 (severe), and total scores were calculated and used in further analyses. Blood samples, BMI and demographic data from CS were collected cross-sectionally.
| Blood collection and clinical laboratory measurements
Blood samples of the participants were collected between 9:00-11:00 AM. Blood (5 mL) was sampled using anticoagulant-free tubes and kept for 1 hour at 4 C (for platelet activation) before serum was isolated (centrifugation at 2000 rpm for 15 minutes at 4 C). Serum was kept at −20 C before testing.
| Metabolic and inflammatory biomarkers assays
Biochip array technology (Randox Biochip, RANDOX Laboratories Ltd, Crumlin, UK, Metabolic Syndrome Array I for Evidence Investigator™) was used to perform simultaneous quantitative detection of multiple analytes from a single serum sample of CS or FEP patient as we have described previously (Kaur, Zilmer, Leping, & Zilmer, 2012 ).
The following inflammatory and metabolic biomarkers: C-peptide, insulin, leptin, resistin, ferritin, IL-6, IL-1α, TNF-α and PAI-1 were measured according to the manufacturer's protocol. Results are expressed as picograms and nanograms per millilitre. The reproducibility of the assay for individual cytokines was determined using the quality control method provided with the kit. Intra-assay and interassay precision are given in Table S1 , Supporting information, units and sensitivity in Table S2 . The plasma concentrations of adiponectin (ng/mL) were analysed by a quantitative sandwich enzyme immunoassay technique, using a commercially available kit (R&D Systems, Minneapolis, MN, USA); intra-assay and inter-assay precision are given in Table S3 .
| Statistical analyses
Group differences with regard to demographic measurements were analysed using the t-test, or Chi-square test. The application of ShapiroWilk tests indicated that the inflammatory and metabolic values were not normally distributed (P < .05). A Mann-Whitney U-test was applied to compare the raw data of two independent samples (FEP patients before treatment and CS) and a Wilcoxon Matched Pairs Test to compare the two dependent samples (FEP patients' pre-and post-treatment condition). For within-subjects analyses, patients were paired one by one. The Bonferroni correction was applied for the number of biomarkers within the particular analysis. Differences between FEP patients and CS (based on the Mann-Whitney U-test), and differences between the pre-and post-treatment values within the patients group (based on the Wilcoxon Matched Pairs Test) were considered significant at P < .05/10, and trends at P < .10/10. Effect sizes were interpreted as small, medium and large, with corresponding eta-squared ranging from 0.01-0.05, 0.06-0.13 and ≥0.14, respectively (Cohen, 1988) .
The Spearman's rank correlation analysis was applied to establish the correlations between metabolic and low-grade inflammation markers, in FEP patients' group (before and after 7-month antipsychotic treatment).
General linear models (GLMs) were used to demonstrate biomarkers levels differences between antipsychotic-naïve FEP patient and CS. Because GLM analyses required normally distributed data, biomarkers values were log 10 -transformed to approximate normality. To establish the treatment main effect (ie, difference between pre-and post-treatment measurement occasion) on BMI and serum biomarkers levels (dependent variables) within-subjects' analysis (GLM:
repeated measures, adjusted for gender and smoking status) were utilized. Categorical (disease, gender and smoking status) and continuous (age) covariates were used in the GLM to compare biomarkers levels (dependent variables) between groups, and P values less than .05 were considered to be statistically significant.
The statistical analyses were performed using Statistical software (StataCorp LP, 2013) for Windows.
3 | RESULTS
| General description of the study groups
There were no statistically significant differences between antipsychotic-naïve FEP patients and CS in terms of age (t = .49, df = 73, P = .62), gender (χ 2 = 1.08, df = 1, P = . was not statistically significant (χ 2 = .05, df = 1, P = .82).
| Correlations between biomarkers
Spearman correlation matrices were generated to explore preliminary relationships among the metabolic and inflammatory markers for preand post-treatment occasions within the FEP patients group. These matrices are shown in Table S4 and Table S5 . As expected, the most prominent positive correlation emerged between insulin and C-peptide.
| Differences in levels of biomarkers between antipsychotic-naïve FEP patients and CS
The comparison of inflammatory and metabolic biomarkers (MannWhitney U-test, raw data) revealed a significant elevation of ferritin and resistin in antipsychotic-naïve FEP patients compared to CS (Table 1) .
Assessment of measured biomarker values difference trends indicated
that patients had higher PAI-1, IL-6 and lower leptin levels compared to CS (Table 1) . According to our sample, differences in the abovementioned biomarker levels demonstrated medium-size effects of the disease. 
| Effects of antipsychotic drugs on psychotic symptoms, BMI and inflammatory and metabolic biomarkers
As expected, there was a statistically significant 7-month antipsychotic treatment effect on the psychopathology (PANSS) total score (t = 10.95, df = 1,70, P < .000001) (GLM-repeated measures). IL-1 α, IL-6, interleukins; TNF-α, tumour necrosis factor-α; PAI-1, plasminogen activator inhibitor-1.
*P values, adjusted with the Bonferroni correction of alpha (.05/10 = .005). Several biomarkers were significantly changed after 7-month antipsychotic treatment in FEP patients (Table 3 ). The strongest decline was established for ferritin, followed by resistin, IL-1α, adiponectin, PAI-1 and IL-6 (Table 3) . Change in ferritin level survives the Bonferroni correction for multiple testing and significant changing trends emerged in the levels of resistin and IL-1α. By contrast, the levels of C-peptide and leptin were significantly elevated after treatment (Table 3 ). The effect size of 7-month antipsychotic treatment on C-peptide, leptin and ferritin levels changes ranged between 0.14 and 0.25, suggesting that the clinical magnitude of the intervention on these markers was strong. Moreover, treatment effect tended to produce a medium effect size in terms of adiponectin, resistin, IL-6, IL-1α, as well as PAI-1 levels changes, and with the large sample size, these biomarkers would have been survived the Bonferroni correction for multiple comparisons.
The number of patients displaying the level of C-peptide higher than 2 pg/mL before treatment was 5 out of 35, whereas after the treatment the respective number of such patients increased to 17.
Moreover, the calculation of ratio between insulin and C-peptide With respect to the differences along the biomarkers levels before and after 7-month antipsychotic treatment, the repeated-measures GLM showed a significant main effect of time accompanied by continuous treatment with antipsychotics on the levels of C-peptide, leptin which were increased and adiponectin which was decreased during the treatment (see Table 4 ). Furthermore, the same model revealed the significant main effect of the treatment condition on BMI, which was elevated significantly during 7 months (Table 4) . Gender and smoking status were not significant predictors in this model. Thereafter, inflammatory and metabolic status of treated FEP patients was compared with CS. Significant difference emerged only in C-peptide level (Table 5) , whereas previously (Table 2 ) demonstrated elevated levels of resistin and ferritin as well as diminished level of leptin were turned into the levels of CS. Age, gender and smoking status were not significant IL-1 α, IL-6, interleukins; TNF-α, tumour necrosis factor-α; PAI-1, plasminogen activator inhibitor-1.
*P values, adjusted with the Bonferroni correction of alpha (.05/10 = .005). predictors with regard to measured biomarkers levels differences between treated FEP group and CS.
| DISCUSSION
Initial comparison of antipsychotic-naïve FEP patients with CS group revealed several apparent differences between these two groups. The levels of ferritin (ie, an acute phase protein), PAI-1 (which has an important role in the regulation of fibrinolysis), IL-6 (ie, a monocyte-/macrophage-related pro-inflammatory cytokine involved predominantly in inflammation and also in the regulation of metabolic processes) and resistin (ie, originally described as an adipocyte-specific hormone, provides a link between obesity, insulin resistance and diabetes) were significantly augmented in antipsychotic-naïve FEP patients. By contrast, the level of leptin (ie, a hormone made by adipose cells, to help regulate energy balance) was reduced in patients before treatment.
The elevation of above-described factors can be taken as a possible sign of inflammatory response during the FEP. This is character- Sengupta et al., 2008) . The discrepancy between our study and previous studies may be partly explained by the sample size.
GLM analysis established a strong positive relationship of disease with ferritin and resistin and inverse relationship with leptin, and confirmed involvement of inflammation and metabolic-related factors during the early stage of the FEP. Adipokines have multidirectional actions or interplay with other molecules in a variety of functions. In rodents, resistin expression is limited to adipose tissue (Steppan et al., 2001) , and is a potential mediator of the obesity and insulin resistance link (Kusminski, Mcternan, & Kumar, 2005) . However, the translation of these findings to humans has been less conclusive (Lazar, 2007) . In humans, resistin appears to be an inflammatory molecule primarily expressed in monocytic cells, from which it is secreted (Patel et al., 2003) . The correlation between resistin with inflammatory markers (eg, IL-6, TNF-α) is particularly noteworthy given the observation that resistin is produced by macrophages in response to inflammatory cytokines (Stejskal, Adamovská, Bartek, Juráková, & Prosková, 2003) , and on the other hand, resistin itself is able to contribute to the inflammatory conditions by mediating enhanced activation of cytokines (IL-6, TNF-α) and nuclear factor kappa B (NF-κB) (Stofkova, 2010) . Thus, the interplay between adipocytes and macrophages may lead to hyper-resistinemia even if human resistin is mainly expressed in macrophages.
Serum ferritin is also a well-known inflammatory marker, and abnormally elevated serum ferritin levels represent a consequence of cell stress and damage (Kell & Pretorius, 2014) . In accordance with our results, a report published by Schwarz et al. (2010) various antipsychotic drugs and while necessary, dosage adjustments and active substance changes were made during the follow-up period. Therefore, it is difficult to draw any major conclusions about the effects of particular antipsychotic drugs. Nevertheless, treatment with antipsychotic drugs caused a significant reduction in the psychopathology total (PANSS) score. However, this positive change was accompanied by the marked increase in BMI, the frequently seen side-effect of antipsychotic medication (Bak, Fransen, Janssen, van Os, & Drukker, 2014; De Hert et al., 2009; McEvoy et al., 2005) . It is important to note that difference in BMI values between antipsychotic-naïve FEP patients and CS was not statistically signifi-
cant. An increase in BMI can be induced by certain antipsychotic drugs (such as olanzapine and clozapine) (Bak et al., 2014; De Hert et al., 2009) , but also by changes in circumstances surrounding the patients, including everyday care. Moreover, the limited physical activity of patients seems to play a role as well. Besides, atypical antipsychotic agents may cause a dysregulation of hormones that control appetite and food intake, such as insulin, leptin and adiponectin (Sentissi, Epelbaum, Olie, & Poirier, 2008) . Altogether, it is apparent that the antipsychotic treatment reduced the indices of inflammation and caused unwanted metabolic alterations already at the early stage of the disease.
We found significant relationships between 7-month antipsychotic treatment and increase in BMI. More importantly, evaluating relationships between antipsychotic usage during the 7-month disease period and BMI as well as selected inflammatory and metabolic biomarkers revealed a significant main effects of the treatment on BMI as well as the levels of C-peptide, leptin and adiponectin (ie, an anti-atherogenic and anti-inflammatory protein that enhances insulin sensitivity and is inversely correlated with BMI). Our results are in agreement with previous studies (Bak et al., 2014; Potvin et al., 2008) suggesting that chronic psychotic disorder is associated with metabolic disturbance, evidenced by elevated levels of C-peptide and leptin. According to our results, the number of patients with C-peptide level higher than 2 pg/mL was raised from 5 to 17 after medication with atypical antipsychotic drugs.
There was a significant shift in favour of C-peptide when the ratio of C- With regard to adiponectin, this biomarker level was significantly decreased among FEP patients after the 7-month treatment. Previously, Bartoli, Lax, Crocamo, Clerici, and Carrà (2015) Some limitations of this study need consideration: first, the limited sample size may create important generalizability problems. Small cohort size in our study arised from the rarity of first-episode, antipsychotic-naïve patients. We suggest that further studies including more patients with a longer follow-up period are necessary to draw a firm conclusion regarding the association between treatment with antipsychotic drugs and the levels of adipose-derived hormones, adipokines and pro-inflammatory markers. Second, we collected data from CS at one point in time and did not control their health condition or metabolic and inflammatory biomarker levels after the same follow-up period as was done for the FEP patients group. Furthermore, we did not evaluate either the participants dietary or their physical activity habits. This is worth to mention, since disease chronicity and continuous antipsychotic treatment may adversely affect lifestyle factors in the group of patients with psychotic disease.
Nevertheless, our findings may shed light on the molecular underpinnings of second-generation antipsychotic-induced MetS and may help to design novel therapeutic approaches to reduce the sideeffects associated with these drugs.
In conclusion, our findings indicate that antipsychotic-naïve FEP patients are characterized by low-grade inflammation evidenced predominantly by increased ferritin level and metabolic disturbance evidenced by elevated level of resistin and declined level of leptin.
Treatment with antipsychotic drugs induced a significant amelioration of psychotic symptoms and caused the elevation in BMI. Simultaneously, 7-month antipsychotic treatment condition was related to elevated levels of C-peptide and leptin, and reduced level of adiponectin. One can conclude that treatment reduces the inflammatory biomarkers, but induces alterations in metabolism evidenced by affected leptin and adiponectin levels and insulin processing. Therefore, it is apparent that one has to find a way how to avoid unwanted changes in the metabolic status of FEP patients.
